Correlation Between Medprin Regenerative and Weihai Honglin

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Medprin Regenerative and Weihai Honglin at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Medprin Regenerative and Weihai Honglin into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Medprin Regenerative Medical and Weihai Honglin Electronic, you can compare the effects of market volatilities on Medprin Regenerative and Weihai Honglin and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Medprin Regenerative with a short position of Weihai Honglin. Check out your portfolio center. Please also check ongoing floating volatility patterns of Medprin Regenerative and Weihai Honglin.

Diversification Opportunities for Medprin Regenerative and Weihai Honglin

-0.34
  Correlation Coefficient

Very good diversification

The 3 months correlation between Medprin and Weihai is -0.34. Overlapping area represents the amount of risk that can be diversified away by holding Medprin Regenerative Medical and Weihai Honglin Electronic in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Weihai Honglin Electronic and Medprin Regenerative is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Medprin Regenerative Medical are associated (or correlated) with Weihai Honglin. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Weihai Honglin Electronic has no effect on the direction of Medprin Regenerative i.e., Medprin Regenerative and Weihai Honglin go up and down completely randomly.

Pair Corralation between Medprin Regenerative and Weihai Honglin

Assuming the 90 days trading horizon Medprin Regenerative is expected to generate 1.28 times less return on investment than Weihai Honglin. But when comparing it to its historical volatility, Medprin Regenerative Medical is 3.04 times less risky than Weihai Honglin. It trades about 0.29 of its potential returns per unit of risk. Weihai Honglin Electronic is currently generating about 0.12 of returns per unit of risk over similar time horizon. If you would invest  1,490  in Weihai Honglin Electronic on November 5, 2024 and sell it today you would earn a total of  117.00  from holding Weihai Honglin Electronic or generate 7.85% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Medprin Regenerative Medical  vs.  Weihai Honglin Electronic

 Performance 
       Timeline  
Medprin Regenerative 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Medprin Regenerative Medical has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Weihai Honglin Electronic 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Weihai Honglin Electronic are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Weihai Honglin sustained solid returns over the last few months and may actually be approaching a breakup point.

Medprin Regenerative and Weihai Honglin Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Medprin Regenerative and Weihai Honglin

The main advantage of trading using opposite Medprin Regenerative and Weihai Honglin positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Medprin Regenerative position performs unexpectedly, Weihai Honglin can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Weihai Honglin will offset losses from the drop in Weihai Honglin's long position.
The idea behind Medprin Regenerative Medical and Weihai Honglin Electronic pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Complementary Tools

Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance